Published in

Wiley, Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 6(9), p. 677-686, 2013

DOI: 10.1016/j.jalz.2012.09.016

Links

Tools

Export citation

Search in Google Scholar

Diagnostic accuracy of markers for prodromal Alzheimer’s disease in independent clinical series

This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

OBJECTIVE: To capitalize on data from different clinical series to compare sensitivity and specificity of individual biomarkers for predicting mild cognitive impairment (MCI) progression to Alzheimer's disease (AD). METHODS: Medial temporal atrophy, cortical hypometabolism, and cerebrospinal fluid biomarkers were assessed in 18 patients with mild cognitive impairment (MCI) with prodromal AD (pAD; conversion time, 26 +/- 12 months) and 18 stable MCI (sMCI) patients from the Translational Outpatient Memory Clinic cohort, as well as in 24 pAD patients (conversion time, 36 +/- 12 months) and 33 sMCI patients from the Alzheimer's Disease Neuroimaging Initiative cohort. Medial temporal atrophy was measured by manual, semi-automated, and automated hippocampal volumetry; cortical hypometabolism was measured using several indices of AD-related hypometabolism pattern; and cerebrospinal fluid markers were amyloid beta (Abeta)42 and total tau protein concentrations. For each biomarker, sensitivity for pAD, specificity for sMCI, and diagnostic accuracy were computed. RESULTS: Sensitivity to predict MCI conversion to AD in the Alzheimer's Disease Neuroimaging Initiative and Translational Outpatient Memory Clinic cohorts was 79% and 94% based on Abeta42, 46% and 28% based on hippocampal volumes, 33% to 66% and 56% to 78% based on different hypometabolism indices, and 46% and 61% based on total tau levels, respectively. Specificity to exclude sMCI was 27% and 50% based on Abeta42, 76% and 94% based on hippocampal volumes, 58% to 67% and 55% to 83% based on different hypometabolism indices, and 61% and 83% based on total tau levels, respectively. CONCLUSIONS: Current findings suggest that Abeta42 concentrations and hippocampal volumes may be used in combination to best identify pAD. ; Prestia, Annapaola Caroli, Anna Herholz, Karl Reiman, Eric Chen, Kewei Jagust, William J Frisoni, Giovanni B Translational Outpatient Memory Clinic Working Group Alzheimer's Disease Neuroimaging Initiative Journal article Alzheimer's & dementia : the journal of the Alzheimer's Association Alzheimers Dement. 2013 Jan 30. pii: S1552-5260(12)02527-7. doi: 10.1016/j.jalz.2012.09.016.